Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2°P-TIMI 50 trial

Vasc Med. 2019 Apr;24(2):159-161. doi: 10.1177/1358863X19826681. Epub 2019 Mar 14.

Authors

Siddharth M Patel¹, David A Morrow², Stephen K Kidd³, Erica L Goodrich², Benjamin M Scirica², Marc P Bonaca²

Affiliations

¹ 1 Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
² 2 TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
³ 3 Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

PMID: 30868939
DOI: 10.1177/1358863X19826681

No abstract available

Keywords: antiplatelet therapy; coronary artery disease; peripheral artery disease (PAD); randomized controlled trials (RCT).

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Age Factors
Aged
Aged, 80 and over
Female
Hemorrhage / chemically induced
Humans
Lactones / adverse effects
Lactones / therapeutic use*
Male
Middle Aged
Myocardial Infarction / prevention & control
Peripheral Arterial Disease / blood
Peripheral Arterial Disease / diagnosis
Peripheral Arterial Disease / drug therapy*
Peripheral Arterial Disease / mortality
Platelet Aggregation Inhibitors / adverse effects
Platelet Aggregation Inhibitors / therapeutic use*
Pyridines / adverse effects
Pyridines / therapeutic use*
Randomized Controlled Trials as Topic
Risk Assessment
Risk Factors
Secondary Prevention / methods*
Stroke / prevention & control
Thrombosis / blood
Thrombosis / diagnosis
Thrombosis / mortality
Thrombosis / prevention & control*
Time Factors
Treatment Outcome

Substances

Lactones
Platelet Aggregation Inhibitors
Pyridines
vorapaxar